Bispecific antibody therapy

Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 25, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Relapsed or Refractory Multiple Myeloma / Treatment Options for Relapsed or Refractory Multiple Myeloma

Bispecific antibodies target both CD3, which is on the surface of T cells, and either BCMA or GPRC5D (G protein–coupled receptor family C group 5 member D), both of which concentrate on the surface of myeloma cells.[48,49]

Source links and citations

Continue within this section

Teclistamab →Talquetamab →Elranatamab →

Publication references

Read the original reference and check its publication notices.

PubMed 35404996 · Original source
PubMed 37471687 · Original source

Preserved source evidence · Not medical advice